Publication:
Barriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia Medicines: A Scoping Review

Simple item page
dc.contributor.authorCastillo-Laborde, Carla
dc.contributor.authorHirmas Adauy, Macarena
dc.contributor.authorMatute, María Isabel
dc.contributor.authorJasmen, Anita
dc.contributor.authorUrrejola, Oscar
dc.contributor.authorMolina, Xaviera
dc.contributor.authorAwad, Camila
dc.contributor.authorFrey, Catalina
dc.contributor.authorPumarino, Sofia
dc.contributor.authorDescalzi, Fernando
dc.contributor.authorRuiz, Tomás
dc.contributor.authorPlass, Barbara
dc.date.accessioned2024-06-12T16:17:16Z
dc.date.available2024-06-12T16:17:16Z
dc.date.issued2022
dc.description.abstractObjective: Identify barriers and facilitators in access to medicines for diabetes, hypertension, and dyslipidemia, considering patient, health provider, and health system perspectives. Methods: Scoping review based on Joanna Briggs methodology. The search considered PubMed, Cochrane Library, CINAHL, Academic Search Ultimate, Web of Science, SciELO Citation Index, and grey literature. Two researchers conducted screening and eligibility phases. Data were thematically analyzed. Results: The review included 219 documents. Diabetes was the most studied condition; most of the evidence comes from patients and the United States. Affordability and availability of medicines were the most reported dimension and specific barrier respectively, both cross-cutting concerns. Among high- and middle-income countries, identified barriers were cost of medicines, accompaniment by professionals, long distances to facilities, and cultural aspects; cost of transportation emerges in low-income settings. Facilitators reported were financial accessibility, trained health workers, medicines closer to communities, and patients' education. Conclusion: Barriers and facilitators are determined by socioeconomic and cultural conditions, highlighting the role of health systems in regulatory and policy context (assuring financial coverage and free medicines); providers' role bringing medicines closer; and patients' health education and disease management.
dc.description.versionPublicada
dc.identifier.citationCastillo-Laborde C, Hirmas-Adauy M, Matute I, Jasmen A, Urrejola O, Molina X, Awad C, Frey-Moreno C, Pumarino-Lira S, Descalzi-Rojas F, Ruiz TJ and Plass B (2022) Barriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia Medicines: A Scoping Review. Public Health Rev 43:1604796. doi: 10.3389/phrs.2022.1604796
dc.identifier.doihttps://doi.org/10.3389/phrs.2022.1604796
dc.identifier.urihttps://hdl.handle.net/11447/9080
dc.language.isoen
dc.subjectAccess
dc.subjectBarriers
dc.subjectDiabetes
dc.subjectDyslipidemia
dc.subjectFacilitators
dc.subjectHypertension (HTN)
dc.subjectMedicines
dc.subjectNon-communicable chronic diseases (NCDs)
dc.titleBarriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia Medicines: A Scoping Review
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourcePublic health reviews
dspace.entity.typePublication
relation.isAuthorOfPublication77a0ad54-bedc-48dd-bc0d-6d6fc521b489
relation.isAuthorOfPublication0f5b4dec-6da8-42d4-a990-05414418e2f4
relation.isAuthorOfPublication1b570626-ec76-4ab9-8c3f-33fca4fa3de4
relation.isAuthorOfPublication.latestForDiscovery77a0ad54-bedc-48dd-bc0d-6d6fc521b489

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Barriers and Facilitators in Access to Diabetes.pdf
Size:
1.98 MB
Format:
Adobe Portable Document Format
Description:
Texto Completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services